Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Keshav Menon is active.

Publication


Featured researches published by Keshav Menon.


Journal of Clinical Investigation | 2013

Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk

Karl Staser; Su Jung Park; Steven D. Rhodes; Yi Zeng; Yong Zheng He; Matthew Shew; Jeffrey R. Gehlhausen; Donna Cerabona; Keshav Menon; Shi Chen; Zejin Sun; Jin Yuan; David A. Ingram; Grzegorz Nalepa; Feng Chun Yang; D. Wade Clapp

Neurofibromatosis type 1 (NF1) predisposes individuals to the development of juvenile myelomonocytic leukemia (JMML), a fatal myeloproliferative disease (MPD). In genetically engineered murine models, nullizygosity of Nf1, a tumor suppressor gene that encodes a Ras-GTPase-activating protein, results in hyperactivity of Raf/Mek/Erk in hematopoietic stem and progenitor cells (HSPCs). Activated Erk1/2 phosphorylate kinases and transcription factors with myriad mitogenic roles in diverse cell types. However, genetic studies examining Erk1/2s differential and/or combined control of normal and Nf1-deficient myelopoiesis are lacking. Moreover, prior studies relying on chemical Mek/Erk inhibitors have reached conflicting conclusions in normal and Nf1-deficient mice. Here, we show that while single Erk1 or Erk2 disruption did not grossly compromise myelopoiesis, dual Erk1/2 disruption rapidly ablated granulocyte and monocyte production in vivo, diminished progenitor cell number, and prevented HSPC proliferation in vitro. Genetic disruption of Erk1/2 in the context of Nf1 nullizygosity (Mx1Cre(+)Nf1(flox/flox)Erk1(-/-)Erk2(flox/flox)) fully protects against the development of MPD. Collectively, we identified a fundamental requirement for Erk1/2 signaling in normal and Nf1-deficient hematopoiesis, elucidating a critical hematopoietic function for Erk1/2 while genetically validating highly selective Mek/Erk inhibitors in a leukemia that is otherwise resistant to traditional therapy.


Human Molecular Genetics | 2015

A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation

Jeffrey R. Gehlhausen; Su Jung Park; Ann E. Hickox; Matthew Shew; Karl Staser; Steven D. Rhodes; Keshav Menon; Jacquelyn D. Lajiness; Muithi Mwanthi; Xianlin Yang; Jin Yuan; Paul R. Territo; Gary D. Hutchins; Grzegorz Nalepa; Feng Chun Yang; Simon J. Conway; Michael G. Heinz; Anat Stemmer-Rachamimov; Charles W. Yates; D. Wade Clapp

Neurofibromatosis type 2 (NF2) is an autosomal dominant genetic disorder resulting from germline mutations in the NF2 gene. Bilateral vestibular schwannomas, tumors on cranial nerve VIII, are pathognomonic for NF2 disease. Furthermore, schwannomas also commonly develop in other cranial nerves, dorsal root ganglia and peripheral nerves. These tumors are a major cause of morbidity and mortality, and medical therapies to treat them are limited. Animal models that accurately recapitulate the full anatomical spectrum of human NF2-related schwannomas, including the characteristic functional deficits in hearing and balance associated with cranial nerve VIII tumors, would allow systematic evaluation of experimental therapeutics prior to clinical use. Here, we present a genetically engineered NF2 mouse model generated through excision of the Nf2 gene driven by Cre expression under control of a tissue-restricted 3.9kbPeriostin promoter element. By 10 months of age, 100% of Postn-Cre; Nf2(flox/flox) mice develop spinal, peripheral and cranial nerve tumors histologically identical to human schwannomas. In addition, the development of cranial nerve VIII tumors correlates with functional impairments in hearing and balance, as measured by auditory brainstem response and vestibular testing. Overall, the Postn-Cre; Nf2(flox/flox) tumor model provides a novel tool for future mechanistic and therapeutic studies of NF2-associated schwannomas.


Human Molecular Genetics | 2016

Nf1+/− monocytes/macrophages induce neointima formation via CCR2 activation

Waylan K. Bessler; Grace Kim; Farlyn Z. Hudson; Julie A. Mund; Raghuveer Singh Mali; Keshav Menon; Reuben Kapur; D. Wade Clapp; David A. Ingram; Brian K. Stansfield

Persons with neurofibromatosis type 1 (NF1) have a predisposition for premature and severe arterial stenosis. Mutations in the NF1 gene result in decreased expression of neurofibromin, a negative regulator of p21(Ras), and increases Ras signaling. Heterozygous Nf1 (Nf1(+/-)) mice develop a marked arterial stenosis characterized by proliferating smooth muscle cells (SMCs) and a predominance of infiltrating macrophages, which closely resembles arterial lesions from NF1 patients. Interestingly, lineage-restricted inactivation of a single Nf1 allele in monocytes/macrophages is sufficient to recapitulate the phenotype observed in Nf1(+/-) mice and to mobilize proinflammatory CCR2+ monocytes into the peripheral blood. Therefore, we hypothesized that CCR2 receptor activation by its primary ligand monocyte chemotactic protein-1 (MCP-1) is critical for monocyte infiltration into the arterial wall and neointima formation in Nf1(+/-) mice. MCP-1 induces a dose-responsive increase in Nf1(+/-) macrophage migration and proliferation that corresponds with activation of multiple Ras kinases. In addition, Nf1(+/-) SMCs, which express CCR2, demonstrate an enhanced proliferative response to MCP-1 when compared with WT SMCs. To interrogate the role of CCR2 activation on Nf1(+/-) neointima formation, we induced neointima formation by carotid artery ligation in Nf1(+/-) and WT mice with genetic deletion of either MCP1 or CCR2. Loss of MCP-1 or CCR2 expression effectively inhibited Nf1(+/-) neointima formation and reduced macrophage content in the arterial wall. Finally, administration of a CCR2 antagonist significantly reduced Nf1(+/-) neointima formation. These studies identify MCP-1 as a potent chemokine for Nf1(+/-) monocytes/macrophages and CCR2 as a viable therapeutic target for NF1 arterial stenosis.


Journal of Bone and Mineral Research | 2015

Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis

Steven D. Rhodes; Hao Yang; Ruizhi Dong; Keshav Menon; Yongzheng He; Zhaomin Li; Shi Chen; Karl Staser; Li Jiang; Xiaohua Wu; Xianlin Yang; Xianghong Peng; Khalid S. Mohammad; Theresa A. Guise; Mingjiang Xu; Feng Chun Yang

Although nullizygous loss of NF1 leads to myeloid malignancies, haploinsufficient loss of NF1 (Nf1) has been shown to contribute to osteopenia and osteoporosis which occurs in approximately 50% of neurofibromatosis type 1 (NF1) patients. Bone marrow mononuclear cells of haploinsufficient NF1 patients and Nf1+/– mice exhibit increased osteoclastogenesis and accelerated bone turnover; however, the culprit hematopoietic lineages responsible for perpetuating these osteolytic manifestations have yet to be elucidated. Here we demonstrate that conditional inactivation of a single Nf1 allele within the myeloid progenitor cell population (Nf1‐LysM) is necessary and sufficient to promote multiple osteoclast gains‐in‐function, resulting in enhanced osteoclastogenesis and accelerated osteoclast bone lytic activity in response to proresorptive challenge in vivo. Surprisingly, mice conditionally Nf1 heterozygous in mature, terminally differentiated osteoclasts (Nf1‐Ctsk) do not exhibit any of these skeletal phenotypes, indicating a critical requirement for Nf1 haploinsufficiency at a more primitive/progenitor stage of myeloid development in perpetuating osteolytic activity. We further identified p21Ras‐dependent hyperphosphorylation of Pu.1 within the nucleus of Nf1 haploinsufficient myelomonocytic osteoclast precursors, providing a novel therapeutic target for the potential treatment of NF1 associated osteolytic manifestations.


Radiology | 2013

Are Current Changes Unprecedented

Richard B. Gunderman; Keshav Menon

Although uncertainty and rapidity of change in radiology may seem like a recent occurrence, the history of radiology in the United States demonstrates that change and instability are the status quo ante.


Journal of Investigative Dermatology | 2006

Parathyroid Hormone Hormone-Related Protein and the PTH Receptor Regulate Angiogenesis of the Skin

A. Godwin Diamond; Ryan M. Gonterman; Aileen L. Anderson; Keshav Menon; Carlos D. Offutt; Chad H. Weaver; William M. Philbrick; John Foley


Differentiation | 2007

Identification of markers for nipple epidermis: changes in expression during pregnancy and lactation

Jennifer Eastwood; Carlos D. Offutt; Keshav Menon; Mitchell Keel; Petra Hrncirova; Milos V. Novotny; Randy J. Arnold; John Foley


PMC | 2016

Nf1+/- monocytes/macrophages induce neointima formation via CCR2 activation

Waylan K. Bessler; Grace Kim; Farlyn Z. Hudson; Julie A. Mund; Raghuveer Singh Mali; Keshav Menon; Reuben Kapur; D. Wade Clapp; David A. Ingram; Brian K. Stansfield


PMC | 2015

Nf1 haploinsufficiency alters myeloid lineage commitment and function, leading to deranged skeletal homeostasis

Steven D. Rhodes; Hao Yang; Ruizhi Dong; Keshav Menon; Yongzheng He; Zhaomin Li; Shi Chen; Karl Staser; Li Jiang; Xiaohua Wu; Xianlin Yang; Xianghong Peng; Khalid S. Mohammad; Theresa A. Guise; Mingjiang Xu; Feng Chun Yang


Blood | 2012

Haploinsufficiency of Nf1 in Myeloid Lineages Contributes to Neurofibromatosis Type 1 Associated Skeletal Deficits

Steven D. Rhodes; Yongzheng He; Shi Chen; Hao Yang; Keshav Menon; Karl Staser; Xianlin Yang; Khalid S. Mohammad; Theresa A. Guise; Mingjiang Xu; Feng Chun Yang

Collaboration


Dive into the Keshav Menon's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge